Nxl104 clinical trials

More Information. National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Drug: [14C]NXL Phase 1. Study Type :. Interventional Clinical Trial. Actual Enrollment :.

Study Start Date :. Actual Primary Completion Date :. Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials. More Information. Publications automatically indexed to this study by ClinicalTrials. Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. Print Nov. National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

Complicated Intra-abdominal Infections. Phase 2. Warning You have reached the maximum number of saved studies Listing a study does not mean it has been evaluated by the U.

Federal Government. Read our disclaimer for details. Results First Posted : May 25, Last Update Posted : May 25, Up to Late follow up LFU visit. Up to LFU visit. Baseline Analysis Population Description Safety population included all participants who received at least 1 dose of study drug. Analysis Population Description. Description Cure: all or most pre-therapy signs and symptoms of the index infection had resolved and no additional antibiotic was required Time Frame End of IV therapy 4 to 14 days Outcome Measure Data Outcome Measure Data.

Description Cure: all or most pre-therapy signs and symptoms of the index infection had resolved and no additional antibiotic was required Time Frame 5 to 9 days post-therapy Outcome Measure Data Outcome Measure Data.

Description Cure: all or most pre-therapy signs and symptoms of the index infection showed no evidence of resurgence and no additional antibiotic was required Time Frame 4 to 6 weeks post-therapy Outcome Measure Data Outcome Measure Data.

National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Complicated Intra-abdominal Infections.

Pre-assignment Details. Period Title: Overall Study. Not Completed. Reason Not Completed. Total of all reporting groups. Baseline Analysis Population Description. Clinical response was defined as complete resolution or significant im Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection.

An AE was any untoward medical occurrence in a participant who receive An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Baseline up to 6 weeks after last dose of study treatment up to a maximum of 8 weeks. Late follow-up visit: 4 to 6 weeks post-therapy up to 8 weeks. Microbiological response was defined as eradication of pathogen identi